Payment overview · 2025
General Payments
$1,260.28
72 reported records · 18 companies
Healthcare provider profile · identity verified
Taylor Eisenmenger, D.O
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, KY · NPI 1477004372
Verified facts
What the public records show
CMS Open Payments records show Taylor Eisenmenger, D.O received $1,260.28 in general payments during 2025 across 72 reported records.
Lilly USA, LLC accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $215.62 | 17.1% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $214.88 | 17.1% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.70 | 11.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $116.55 | 9.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $115.07 | 9.1% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $92.97 | 7.4% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.85 | 6.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.00 | 3.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.53 | 3.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.06 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.88 | 2.0% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.61 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.35 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.82 | 1.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.02 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.60 | 1.4% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.82 | 1.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.95 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,260.28 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $214.88 | 20 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $158.23 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $158.23 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $142.70 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $142.70 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $142.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.07 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.36 | 6 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $77.85 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $77.85 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $76.12 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.12 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.12 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $57.39 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $49.43 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $49.43 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.43 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $47.00 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.53 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.06 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.88 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 115 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 103 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 115 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1295 | 375 |
| Amlodipine Besylate | Amlodipine Besylate | 854 | 246 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 690 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 406 | 108 |
| Losartan Potassium | Losartan Potassium | 377 | 105 |
| Omeprazole | Omeprazole | 341 | 103 |
| Lisinopril | Lisinopril | 286 | 89 |
| Metformin Hcl Er | Metformin Hcl | 274 | 84 |
| Furosemide | Furosemide | 259 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 70 |
| Alprazolam | Alprazolam | 242 | 49 |
| Ezetimibe | Ezetimibe | 240 | 61 |
| Sertraline Hcl | Sertraline Hcl | 200 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 56 |
| Metformin Hcl | Metformin Hcl | 186 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 180 | 49 |
| Potassium Chloride | Potassium Chloride | 171 | 54 |
| Alendronate Sodium | Alendronate Sodium | 169 | 40 |
| Gabapentin | Gabapentin | 168 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 166 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 56 |
| Irbesartan | Irbesartan | 158 | 39 |
| Famotidine | Famotidine | 154 | 39 |
| Montelukast Sodium | Montelukast Sodium | 146 | 44 |
| Trazodone Hcl | Trazodone Hcl | 144 | 45 |
| Meloxicam | Meloxicam | 143 | 50 |
| Simvastatin | Simvastatin | 138 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | 38 |
| Chlorthalidone | Chlorthalidone | 136 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 29 |
| Carvedilol | Carvedilol | 116 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 34 |
| Eliquis | Apixaban | 115 | 29 |
| Jardiance | Empagliflozin | 115 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 31 |
| Glipizide | Glipizide | 109 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 33 |
| Farxiga | Dapagliflozin Propanediol | 103 | 21 |
| Buspirone Hcl | Buspirone Hcl | 97 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 38 |
| Allopurinol | Allopurinol | 90 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 90 | 33 |
| Repatha Sureclick | Evolocumab | 87 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 86 | 26 |
| Glimepiride | Glimepiride | 85 | 21 |
| Telmisartan | Telmisartan | 82 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 26 |
| Synthroid | Levothyroxine Sodium | 71 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 69 | 19 |
| Januvia | Sitagliptin Phosphate | 67 | 11 |
| Diazepam | Diazepam | 61 | 13 |
| Lorazepam | Lorazepam | 60 | 18 |
| Benazepril Hcl | Benazepril Hcl | 58 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 11 |
| Ozempic | Semaglutide | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 17 |
| Atenolol | Atenolol | 48 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 41 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | 20 |
| Rybelsus | Semaglutide | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 11 |
| Propranolol Hcl | Propranolol Hcl | 40 | 11 |
| Valsartan | Valsartan | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 17 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 28 |
| Azelastine Hcl | Azelastine Hcl | 28 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 12 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | 12 |
| Methocarbamol | Methocarbamol | 27 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Prednisone | Prednisone | 26 | 11 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,260.28 · 72 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, GARDASIL 9, GEMTESA, HETLIOZ, Heplisav-B, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tlando, VOQUEZNA, VRAYLAR, Veozah, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error